Handelsbanken Fonder AB Boosts Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Handelsbanken Fonder AB boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 392,981 shares of the medical research company’s stock after buying an additional 2,320 shares during the period. Thermo Fisher Scientific makes up about 1.0% of Handelsbanken Fonder AB’s holdings, making the stock its 14th biggest position. Handelsbanken Fonder AB owned approximately 0.10% of Thermo Fisher Scientific worth $243,086,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of TMO. Campbell & CO Investment Adviser LLC acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at $382,000. Cetera Advisor Networks LLC raised its stake in shares of Thermo Fisher Scientific by 0.8% during the 4th quarter. Cetera Advisor Networks LLC now owns 27,441 shares of the medical research company’s stock worth $14,566,000 after buying an additional 229 shares during the last quarter. Exencial Wealth Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 31.5% during the 4th quarter. Exencial Wealth Advisors LLC now owns 965 shares of the medical research company’s stock worth $512,000 after buying an additional 231 shares during the last quarter. Morningstar Investment Services LLC raised its stake in shares of Thermo Fisher Scientific by 222.5% during the 4th quarter. Morningstar Investment Services LLC now owns 2,464 shares of the medical research company’s stock worth $1,313,000 after buying an additional 1,700 shares during the last quarter. Finally, CenterBook Partners LP raised its stake in shares of Thermo Fisher Scientific by 5.0% during the 4th quarter. CenterBook Partners LP now owns 3,696 shares of the medical research company’s stock worth $1,962,000 after buying an additional 176 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $180,255.00. Following the transaction, the executive vice president now directly owns 17,887 shares in the company, valued at $10,747,403.95. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 23,084 shares of company stock valued at $14,094,292. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on TMO. Royal Bank of Canada reaffirmed an “outperform” rating and set a $767.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, September 20th. Barclays cut their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating for the company in a research note on Friday, June 28th. TD Cowen lifted their price target on Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Stifel Nicolaus boosted their target price on shares of Thermo Fisher Scientific from $615.00 to $680.00 and gave the company a “buy” rating in a research note on Friday, September 20th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research note on Friday, September 20th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average target price of $653.72.

Thermo Fisher Scientific Trading Down 0.4 %

Shares of NYSE:TMO traded down $2.31 during trading on Friday, reaching $598.61. 871,514 shares of the stock were exchanged, compared to its average volume of 1,279,872. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $627.88. The firm has a market cap of $228.67 billion, a price-to-earnings ratio of 38.40, a price-to-earnings-growth ratio of 3.88 and a beta of 0.77. The firm’s 50-day moving average price is $609.46 and its 200 day moving average price is $582.78.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The business had revenue of $10.54 billion during the quarter, compared to analysts’ expectations of $10.50 billion. During the same quarter in the previous year, the business earned $5.15 EPS. The company’s revenue for the quarter was down 1.4% on a year-over-year basis. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.26%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.